Systematic review suggests biologics may improve outcomes in chronic rhinosinusitis with nasal polyps

This systematic review examined the effectiveness and safety of biologics (dupilumab, omalizumab, mepolizumab, stapokibart) for chronic rhinosinusitis with nasal polyps (CRSwNP), often in patients with comorbid type 2 conditions like asthma. The review synthesized data from clinical trials and real-world evidence but did not report specific sample sizes, study settings, or follow-up duration.

The review found biologics may enhance quality of life, reduce the need for systemic corticosteroid therapy, decrease the need for endoscopic sinus surgery, and improve management of comorbid conditions. However, the review did not provide effect sizes, absolute numbers, p-values, confidence intervals, or comparative efficacy data between different biologics or between biologics and endoscopic sinus surgery. Safety and tolerability data were not reported.

Key limitations include the qualitative nature of the findings without quantitative measures of effect. The review includes stapokibart, which is approved in China but not by the US FDA. Practice relevance is limited as the review summarizes existing evidence rather than providing new comparative effectiveness or safety data to guide clinical decision-making between treatment options.